ASCO Annual Meeting: Thyroid Cancer | Conference

Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid Cancer
July 17, 2021

Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

Thyroid Cancer Diagnosis Affects Employment, Income
June 25, 2015

Survivors of thyroid cancer had a higher risk of unemployment at 2 years post-diagnosis and decreased income at both 2 and 4 years, according to the results of a study.

FNA Analysis Could Help Predict Thyroid Cancer Recurrence Risk
June 22, 2015

Use of transcriptional data taken from the FNA of thyroid nodules could help in predicting recurrence post surgery in certain thyroid cancer patients.

SELECT Subanalyses Provide Patient Selection Insight for Lenvatinib
June 11, 2015

Two subgroup analyses of the SELECT trial could help clarify which differentiated thyroid carcinoma patients will benefit most from lenvatinib.

First-Line Lenvatinib May Improve PFS in Thyroid Cancer
June 10, 2015

First-line lenvatinib may improve progression-free survival in patients with 131I-refractory differentiated thyroid cancer with no prior history of VEGF therapy.

Everolimus Active in Thyroid Cancer After Sorafenib Progression
June 10, 2015

Adding everolimus to sorafenib at the time of progression of advanced radio-iodine refractory differentiated thyroid carcinoma was tolerable and active.

EXAM: Cabozantinib Doubled Survival in Medullary Thyroid Carcinoma With RET M918T Mutation
June 10, 2015

In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.

Final Cabozantinib OS Results Fail to Show Improvement
June 04, 2015

Cabozantinib failed to significantly increase overall survival compared with placebo in patients with medullary thyroid carcinoma, according to the EXAM study.

Thyroid Cancer Growth Rate Provided Insight Into Sorafenib Efficacy
May 31, 2015

Tumor growth rate analysis may be a valuable efficacy parameter to consider in patients with sorafenib-treated, radioiodine-refractory differentiated thyroid cancer.